1st Quarter - Report

BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY

Firm
Client
Income
—
Expenses
$600,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions OECD Implementation

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
LANE PENRY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Intellectual Property Reform concerning bio-pharmaceutical industry Trade-Related aspects of Intellectual Property (TRIPS) Waiver

LobbyistCovered position, as disclosed
THOMAS BRUNET —
LANE PENRY —
PAUL ANTHONY WILLIAMS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Discussions regarding health equity H.R.830, HELP Copays Act of 2023 H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Biosimilars reimbursement issues International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act

LobbyistCovered position, as disclosed
THOMAS BRUNET —
STEPHANIE A. DYSON —
KATHRYN NOVARIA —
LANE PENRY —
CAROLINE TUCKER —
PAUL ANTHONY WILLIAMS —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4895 (118th), H.R. 830 (118th), H.R. 3561 (118th)

Medicare/Medicaid MMM

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation H.R.7625, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
KATHRYN NOVARIA —
LANE PENRY —
PAUL ANTHONY WILLIAMS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2163 (118th), H.R. 7625 (118th), H.R. 2071 (118th)

Pharmacy PHA

S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act H.R.6283, 118th Congress: DRUG Act H.R.2880, Protecting Patients Against PBM Abuses Act

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
KATHRYN NOVARIA —
LANE PENRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1339 (118th), H.R. 5378 (118th), S. 127 (118th), H.R. 6283 (118th), S. 2973 (118th), H.R. 3283 (118th), H.R. 2880 (118th)

Manufacturing MAN

Issues regarding supply chain

LobbyistCovered position, as disclosed
JOHN DEOUDES —
KATHRYN NOVARIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.